Hansen Medical receives FDA clearance for CoHesion Module
Hansen Medical Inc. (Nasdaq:HNSN) said early Wednesday it had received clearance from the U.S. Food and Drug Administration to market its CoHesion 3D Visualization Module. The product is intended for use in complex electrophysiology mapping procedures, the Mountain View, Calif.-based company said. The CoHesion product will allow doctors to navigate a catheter during the diagnostic phase of a cardiac arrhythmia procedure, the company said. Hansen Medical produces a family of medical robotics designed for use in the medical field.
On Wednesday, shares of Hansen Medical rose slightly to $17.49, up 4.6% from Tuesday’s close.
For detailed price information and recent news stories on Hansen Medical Inc., click HNSN.
